Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Background. Sodium-glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase-4 (DPP-4) inhibitors are glucose-lowering drugs whose anti-inflammatory properties have recently become useful in tackling metabolic syndromes in chronic inflammatory diseases, including diabetes and obesity. We investigated whether empagliflozin (SGLT2 inhibitor) and gemigliptin (DPP-4 inhibitor) improve inflammatory responses in macrophages, identified signalling pathways responsible for these effects, and studied whether the effects can be augmented with dual empagliflozin and gemigliptin therapy. Methods. RAW 264.7 macrophages were first stimulated with lipopolysaccharide (LPS), then cotreated with empagliflozin, gemigliptin, or empagliflozin plus gemigliptin. We conducted quantitative RT-PCR (qRT-PCR) to determine the most effective anti-inflammatory doses without cytotoxicity. We performed ELISA and qRT-PCR for inflammatory cytokines and chemokines and flow cytometry for CD80, the M1 macrophage surface marker, to evaluate the anti-inflammatory effects of empagliflozin and gemigliptin. NF-κB, MAPK, and JAK2/STAT signalling pathways were examined via Western blotting to elucidate the molecular mechanisms of anti-inflammation. Results. LPS-stimulated CD80+ M1 macrophages were suppressed by coincubation with empagliflozin, gemigliptin, and empagliflozin plus gemigliptin, respectively. Empagliflozin and gemigliptin (individually and combined) inhibited prostaglandin E2 (PGE2) release and COX-2, iNOS gene expression in LPS-stimulated RAW 264.7 macrophages. These three treatments also attenuated the secretion and mRNA expression of proinflammatory cytokines, such as TNF-α, IL-1β, IL-6, and IFN-γ, and proinflammatory chemokines, such as CCL3, CCL4, CCL5, and CXCL10. All of them blocked NF-κB, JNK, and STAT1/3 phosphorylation through IKKα/β, MKK4/7, and JAK2 signalling. Conclusions. Our study demonstrated the anti-inflammatory effects of empagliflozin and gemigliptin via IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 pathway downregulation in macrophages. In all cases, combined empagliflozin and gemigliptin treatment showed greater anti-inflammatory properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Empagliflozin was proven to mitigate inflammation by downregulation of the JAK2/STAT1 pathway in macrophages [89].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
NF-κB signaling in inflammation
Liu, T., Zhang, L., Joo, D., & Sun, S.-C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.23 · Cited by 8,791
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679 · cited 1×
“NF-κB is a crucial transcription factor for proinflammatory mediators in macrophages [46].”
BackgroundInflammatory links between obesity and metabolic disease
Lumeng, C. N., & Saltiel, A. R. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57132 · Cited by 2,319 · cited 1×
“Certain aspects of chronic low-grade inflammation in obesity and metabolic syndrome-related diseases, such as hypertension, atherosclerosis, and diabetes mellitus, have been studied [1].”
BackgroundInflammation as a link between obesity, metabolic syndrome and type 2 diabetes
Esser, N., Legrand-Poels, S., Piette, J., Scheen, A. J., & Paquot, N. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.006 · Cited by 1,981
Pathophysiology of acute wound healing
Li, J., Chen, J., & Kirsner, R. (2007) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2006.09.007 · Cited by 1,486
Kaminska, B. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.08.017 · Cited by 1,285 · cited 1×
“MAPKs mediate biological processes and cellular responses to external stimuli, such as LPS [42, 47].”
BackgroundTNF and ROS crosstalk in inflammation
Blaser, H., Dostert, C., Mak, T. W., & Brenner, D. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.12.002 · Cited by 1,008
Kanai, Y., Lee, W. S., You, G., Brown, D., & Hediger, M. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116972 · Cited by 630
Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608 · cited 1×
“7nM), but the selectivity for SGLT1 (IC50 8,300nM) was much weaker than that of canagliflozin (IC50 710nM) [56].”
BackgroundThe sodium/glucose cotransport family SLC5
Wright, E. M., & Turk, E. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1202-0 · Cited by 537 · cited 1×
“Sodium-glucose cotransporters are a family of active glucose transporter proteins expressed in bacteria and animals, including 12 human genes [5, 6].”
BackgroundXu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.028 · Cited by 493 · cited 1×
“These antidiabetic agents have been recently reported to promote M2 macrophage polarization with an anti-inflammatory phenotype and to attenuate the production of proinflammatory cytokines on diabetic cardiomyopathy and nephropathy in mice [14, 15].”
BackgroundProstaglandin E2-induced inflammation: Relevance of prostaglandin E receptors
Kawahara, K., Hohjoh, H., Inazumi, T., Tsuchiya, S., & Sugimoto, Y. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.07.008 · Cited by 488
Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
Klemann, C., Wagner, L., Stephan, M., & von Hörsten, S. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12781 · Cited by 425 · cited 1×
“It acts as an enzymatic and nonenzymatic multifunctional protein, depending on the expressing cell type and cellular conditions, by regulating peptides or influencing cell signals [18, 25, 26].”
BackgroundSystematic validation of specific phenotypic markers for in vitro polarized human macrophages
Ambarus, C. A., Krausz, S., van Eijk, M., Hamann, J., Radstake, T. R. D. J., Reedquist, K. A., Tak, P. P., & Baeten, D. L. P. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.10.013 · Cited by 411
The Role of SGLT1 and GLUT2 in Intestinal Glucose Transport and Sensing
Röder, P. V., Geillinger, K. E., Zietek, T. S., Thorens, B., Koepsell, H., & Daniel, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089977 · Cited by 408
Van Ginderachter, J. A., Movahedi, K., Hassanzadeh Ghassabeh, G., Meerschaut, S., Beschin, A., Raes, G., & De Baetselier, P. (2006) · Immunobiology · doi:10.1016/j.imbio.2006.06.002 · Cited by 371 · cited 9×
“Empagliflozin and gemigliptin (individually and combined) inhibited prostaglandin E2 (PGE2) release and COX-2, iNOS gene expression in LPS-stimulated RAW 264.7 macrophages.”
BackgroundInfluentialYe, Y., Bajaj, M., Yang, H.-C., Perez-Polo, J. R., & Birnbaum, Y. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6725-2 · Cited by 368 · cited 2×
“These antidiabetic agents have been recently reported to promote M2 macrophage polarization with an anti-inflammatory phenotype and to attenuate the production of proinflammatory cytokines on diabetic cardiomyopathy and nephropathy in mice [14, 15].”
BackgroundNitric oxide and cell viability in inflammatory cells: a role for NO in macrophage function and fate
Boscá, L., Zeini, M., Través, P. G., & Hortelano, S. (2005) · Toxicology · doi:10.1016/j.tox.2004.11.035 · Cited by 356
The multifunctional or moonlighting protein CD26/DPPIV
Boonacker, E., & Van Noorden, C. J. F. (2003) · European Journal of Cell Biology · doi:10.1078/0171-9335-00302 · Cited by 337 · cited 1×
“It acts as an enzymatic and nonenzymatic multifunctional protein, depending on the expressing cell type and cellular conditions, by regulating peptides or influencing cell signals [18, 25, 26].”
BackgroundFeng, G.-J., Goodridge, H. S., Harnett, M. M., Wei, X.-Q., Nikolaev, A. V., Higson, A. P., & Liew, F.-Y. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.12.6403 · Cited by 335
Durinx, C., Lambeir, A., Bosmans, E., Falmagne, J., Berghmans, R., Haemers, A., Scharpé, S., & De Meester, I. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01634.x · Cited by 267
The sodium/glucose cotransport family SLC5
Turk, E., & Wright, E. M. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1063-6 · Cited by 251
Esser, N., Paquot, N., & Scheen, A. J. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.974804 · Cited by 250
Mancini, S. J., Boyd, D., Katwan, O. J., Strembitska, A., Almabrouk, T. A., Kennedy, S., Palmer, T. M., & Salt, I. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-23420-4 · Cited by 240 · cited 1×
“One SGLT2 inhibitor, canagliflozin, but neither dapagliflozin nor empagliflozin, inhibited proinflammatory cytokine IL-6 in an AMP-activated protein kinase- (AMPK) dependent manner in human endothelial cells (HUVECs) [55].”
BackgroundDipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions
Shao, S., Xu, Q., Yu, X., Pan, R., & Chen, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107503 · Cited by 221
Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1)
Zhou, L., Cryan, E. V., D'Andrea, M. R., Belkowski, S., Conway, B. R., & Demarest, K. T. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10631 · Cited by 206
Jojima, T., Tomotsune, T., Iijima, T., Akimoto, K., Suzuki, K., & Aso, Y. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0169-x · Cited by 202 · cited 2×
“In the mouse hepatic inflammation model [59], empagliflozin reduced the number of F4/80 M1 macrophages and the mRNA expression of proinflammatory cytokines by attenuating NF-κB and JNK phosphorylation.”
BackgroundInhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes
Pratley, R. E., & Salsali, A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x162746 · Cited by 195
Type 2 diabetes—Therapy with dipeptidyl peptidase IV inhibitors
Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.05.010 · Cited by 192 · cited 1×
“It acts as an enzymatic and nonenzymatic multifunctional protein, depending on the expressing cell type and cellular conditions, by regulating peptides or influencing cell signals [18, 25, 26].”
BackgroundOgata, S., Misumi, Y., & Ikehara, Y. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)94108-6 · Cited by 180
Zhong, J., Rao, X., Deiuliis, J., Braunstein, Z., Narula, V., Hazey, J., Mikami, D., Needleman, B., Satoskar, A. R., & Rajagopalan, S. (2013) · Diabetes · doi:10.2337/db12-0230 · Cited by 176 · cited 1×
“DPP-4 aids macrophage and dendritic cell maturation, consequently inducing T-cell activation, and has recently emerged as an important inflammatory response regulator [24, 27, 28].”
BackgroundShiba, K., Tsuchiya, K., Komiya, C., Miyachi, Y., Mori, K., Shimazu, N., Yamaguchi, S., Ogasawara, N., Katoh, M., Itoh, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19658-7 · Cited by 175 · cited 2×
“[17] recently confirmed SGLT2 protein expression in RAW 264.”
BackgroundAntidiabetic agents: Potential anti-inflammatory activity beyond glucose control
Scheen, A. J., Esser, N., & Paquot, N. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.02.003 · Cited by 171 · cited 1×
“Currently, antidiabetic drugs are in the spotlight for their antiinflammatory properties [53].”
BackgroundPanayotova-Heiermann, M., Loo, D. D. F., & Wright, E. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.27099 · Cited by 165 · cited 3×
“glycosuria by competitively inhibiting both SGLT1 and SGLT2 [13].”
BackgroundInfluentialThe Role of STATs in Inflammation and Inflammatory Diseases
E. Pfitzner, B. S. P., S. Kliem, B. S. P., D. Baus, B. S. P., & M. C. Litterst, B. S. P. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383638 · Cited by 164 · cited 1×
“STATs are another important group of transcription factors in a variety of cytokines and growth factors for mediating pro- and anti-inflammatory responses [43].”
BackgroundXu, C., Wang, W., Zhong, J., Lei, F., Xu, N., Zhang, Y., & Xie, W. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.03.013 · Cited by 161 · cited 2×
“7 macrophages were treated with the various doses of empagliflozin (40, 60, and 80μM) or gemigliptin (100, 250, and 500μM) for 4 h (Figures 1(a) and 1(b)) [16, 35].”
BackgroundMethodEffects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys
Yaribeygi, H., Katsiki, N., Butler, A. E., & Sahebkar, A. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.08.005 · Cited by 147
A new family of serine-type peptidases related to prolyl oligopeptidase
Rawlings, N. D., Polgár, L., & Barrett, A. J. (1991) · Biochemical Journal · doi:10.1042/bj2790907 · Cited by 143
Structure of the human Na+/glucose cotransporter gene SGLT1.
Turk, E., Martín, M. G., & Wright, E. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36592-4 · Cited by 132
CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1
Ohnuma, K., Yamochi, T., Uchiyama, M., Nishibashi, K., Yoshikawa, N., Shimizu, N., Iwata, S., Tanaka, H., Dang, N. H., & Morimoto, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405266101 · Cited by 126 · cited 1×
“Soluble DPP-4 (sDPP-4) activates immune response by upregulating CD86 (M1 macrophage marker) expression in antigen-presenting cells (APCs) via interleukin-1 receptorrelated kinase 1 (IRAK-1) and NF-κB signalling pathways [60, 61].”
BackgroundJeon, Y. J., Han, S. H., Lee, Y. W., Lee, M., Yang, K. H., & Kim, H. M. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00199-5 · Cited by 126 · cited 1×
“We also used dexamethasone, a well-known anti-inflammatory reagent, as a positive control to compare the efficacy of empagliflozin and gemigliptin [44, 45].”
MethodSelf-citationRegional distribution of SGLT activity in rat brain in vivo
Yu, A. S., Hirayama, B. A., Timbol, G., Liu, J., Diez-Sampedro, A., Kepe, V., Satyamurthy, N., Huang, S.-C., Wright, E. M., & Barrio, J. R. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00317.2012 · Cited by 126
Hinz, B., Brune, K., & Pahl, A. M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2859 · Cited by 123
Birnbaum, Y., Bajaj, M., Yang, H., & Ye, Y. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6778-x · Cited by 123 · cited 1×
“Another combination therapy with dapagliflozin and saxagliptin ameliorated diabetic cardiomyopathy and diabetic nephropathy in mice by inhibiting proinflammatory cytokines and NLRP3/ASC inflammasome production [15, 64].”
BackgroundScheen, A. J. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1215427 · Cited by 110 · cited 1×
“Combination therapy of SGLT2 and DPP-4 inhibitors has a stronger glucose-lowering effect than either monotherapy in type 2 diabetes patients due to different mechanisms and complementary effects [34].”
BackgroundThe sodium/substrate symporter family: structural and functional features
Jung, H. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03184-8 · Cited by 109 · cited 1×
“Sodium-glucose cotransporters are a family of active glucose transporter proteins expressed in bacteria and animals, including 12 human genes [5, 6].”
BackgroundDipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism
Trzaskalski, N. A., Fadzeyeva, E., & Mulvihill, E. E. (2020) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551420912972 · Cited by 96 · cited 1×
“DPP-4 aids macrophage and dendritic cell maturation, consequently inducing T-cell activation, and has recently emerged as an important inflammatory response regulator [24, 27, 28].”
BackgroundAnti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?
Katsiki, N., & Ferrannini, E. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107723 · Cited by 91 · cited 1×
“There is a meta-analysis to show C-reactive protein and proinflammatory cytokine IL-6 reduction in people treated with at least one SGLT2 or DPP-4 inhibitor among patients confirmed with coronavirus infection [54].”
BackgroundTomović, K., Lazarević, J., Kocic, G. M., Deljanin-Ilić, M., Anderluh, M., & Šmelcerović, A. (2018) · Medicinal Research Reviews · doi:10.1002/med.21513 · Cited by 88
Birnbaum, Y., Bajaj, M., Qian, J., & Ye, Y. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000227 · Cited by 87 · cited 1×
“DPP-4 inhibitors also attenuated NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome activation, reducing proinflammatory cytokine productions in diabetic mouse kidney and heart [32, 33].”
BackgroundPreller, V., Gerber, A., Wrenger, S., Togni, M., Marguet, D., Tadje, J., Lendeckel, U., Röcken, C., Faust, J., Neubert, K., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4632 · Cited by 86 · cited 1×
“DPP-4 aids macrophage and dendritic cell maturation, consequently inducing T-cell activation, and has recently emerged as an important inflammatory response regulator [24, 27, 28].”
BackgroundDPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
Carolyn, F. D. (2007) · Frontiers in bioscience · doi:10.2741/2799 · Cited by 84
Uthman, L., Kuschma, M. C., Römer, G., Boomsma, M., Keßler, J., Hermanides, J., Hollmann, M. W., Preckel, B., Zuurbier, C. J., & Weber, N. C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07083-w · Cited by 77
Lee, S.-G., Lee, S.-J., Lee, J.-J., Kim, J.-S., Lee, O.-H., Kim, C.-K., Kim, D., Lee, Y.-H., Oh, J., Park, S., et al. (2020) · Korean Circulation Journal · doi:10.4070/kcj.2019.0296 · Cited by 75 · cited 1×
“Dapagliflozin also suppressed iNOS, TNF-α, IL-1β, and IL-6 mRNA expression by attenuating the NF-κB transcription factor in dietinduced atherosclerosis in rat aortic arteries [58].”
BackgroundSelf-citationBirnbaum, Y., Tran, D., Bajaj, M., & Ye, Y. (2019) · Basic Research in Cardiology · doi:10.1007/s00395-019-0743-0 · Cited by 72 · cited 1×
“DPP-4 inhibitors also attenuated NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome activation, reducing proinflammatory cytokine productions in diabetic mouse kidney and heart [32, 33].”
BackgroundIkedo, T., Minami, M., Kataoka, H., Hayashi, K., Nagata, M., Fujikawa, R., Higuchi, S., Yasui, M., Aoki, T., Fukuda, M., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004777 · Cited by 64
Shinjo, T., Nakatsu, Y., Iwashita, M., Sano, T., Sakoda, H., Ishihara, H., Kushiyama, A., Fujishiro, M., Fukushima, T., Tsuchiya, Y., et al. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00553.2014 · Cited by 59
Soluble CD26/Dipeptidyl Peptidase IV Induces T Cell Proliferation Through CD86 Up-Regulation on APCs
Ohnuma, K., Munakata, Y., Ishii, T., Iwata, S., Kobayashi, S., Hosono, O., Kawasaki, H., Dang, N. H., & Morimoto, C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.6745 · Cited by 58 · cited 1×
“Soluble DPP-4 (sDPP-4) activates immune response by upregulating CD86 (M1 macrophage marker) expression in antigen-presenting cells (APCs) via interleukin-1 receptorrelated kinase 1 (IRAK-1) and NF-κB signalling pathways [60, 61].”
BackgroundHwang, H., Chung, H. S., Jung, T. W., Ryu, J. Y., Hong, H. C., Seo, J. A., Kim, S. G., Kim, N. H., Choi, K. M., Choi, D. S., et al. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.01.025 · Cited by 54 · cited 2×
“Gemigliptin reduced proinflammatory cytokines by attenuating NF-κB and JNK signalling via an Akt- and AMPK-dependent mechanism in LPS-induced human monocytic THP-1 cells [35].”
BackgroundMethodLi, Q., Dong, D.-D., Huang, Q., Li, J., Du, Y.-Y., Li, B., Li, H., & Huyan, T. (2017) · Pharmaceutical Biology · doi:10.1080/13880209.2017.1280514 · Cited by 43 · cited 1×
“We also used dexamethasone, a well-known anti-inflammatory reagent, as a positive control to compare the efficacy of empagliflozin and gemigliptin [44, 45].”
MethodDistribution of adenosine deaminase complexing protein (ADCP) in human tissues.
Dinjens, W. N. M., ten Kate, J., van der Linden, E. P. M., Wijnen, J., Khan, P. M., & Bosman, F. T. (1989) · Journal of Histochemistry & Cytochemistry · doi:10.1177/37.12.2573631 · Cited by 41
Heike, M., Möbius, U., Knuth, A. K., Meuer, S. C., & Büschenfelde, K. H. M. Z. (1988) · PubMed Central · Cited by 38
Glucose transport in lymphocytes
Lang, F. J. W., Singh, Y., Salker, M. S., Ma, K., Pandyra, A. A., Lang, P. A., & Lang, K. S. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02416-y · Cited by 29
Anti-inflammatory properties of antidiabetic agents
Xourgia, E., Tzouganatou, E.-M., Papazafiropoulou, A. K., & Melidonis, A. I. (2019) · World Journal of Meta-Analysis · doi:10.13105/wjma.v7.i4.129 · Cited by 12
Cited by
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
“Empagliflozin was proven to mitigate inflammation by downregulation of the JAK2/STAT1 pathway in macrophages [89].”
BackgroundSodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
Fonseca-Correa, J. I., & Correa-Rotter, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.777861 · Cited by 277
Cai, C., Guo, Z., Chang, X., Li, Z., Wu, F., He, J., Cao, T., Wang, K., Shi, N., Zhou, H., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102288 · Cited by 261
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 256
Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910822 · Cited by 191
“SGLT2i - Promote autophagic potential of renal cells (induction of AMPK phosphorylation AMPK) [24] - Decrease activity of mammalian target of rapamycin (mTOR) [24,68] - Decrease synthesis of proinflammatory cytokines: interleukin 1β (IL1β), interleukin 6 (IL6) and tumor necrosis factor α (TNFα) through inhibition of N…”
BackgroundInfluential
Metadata
- Authors
- Lee, N., Heo, Y. J., Choi, S.-E., Jeon, J. Y., Han, S. J., Kim, D. J., Kang, Y., Lee, K. W., & Kim, H. J.
- Affiliations
- Ajou University (KR)
- Corresponding author
- Kim, Hae Jin
- ORCID
- Venue
- Journal of Immunology Research
- Publisher
- Wiley
- Published
- 2021-06-02
- Volume
- 2021
- Pages
- 1-11
- ISSN
- 2314-7156 (ISSN-L)
- 2314-8861
- PMC
- PMC8192181
- OpenAlex
- W3169937201
- Cited by
- 139
- References
- 66
- Citations by year
- 2026: 19 · 2025: 30 · 2024: 29 · 2023: 36 · 2022: 20 · 2021: 5
- FWCI
- 16.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Immunology Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- AJOU Open Repository (Ajou University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation of Korea (NRF-2020R1F1A1074019)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Keywords
- empagliflozin, gemigliptin, SGLT2 inhibitors, DPP-4 inhibitors, anti-inflammatory activity, macrophages, lipopolysaccharide, NF-κB signaling, JNK signaling, JAK2/STAT3, M1 macrophages, inflammatory cytokines, chemokines, prostaglandin E2, cyclooxygenase-2, inducible nitric oxide synthase, dual therapy, diabetes mellitus, obesity
- MeSH terms
- RAW 264.7 Cells, Sodium-Glucose Transporter 2 Inhibitors, Animals, Anti-Inflammatory Agents, Benzhydryl Compounds, Glucosides, Lipopolysaccharides, Macrophage Activation, Macrophages, Piperidones, Pyrimidines, Signal Transduction, NF-kappa B, MAP Kinase Kinase 4, MAP Kinase Kinase 7, STAT1 Transcription Factor, Mice, I-kappa B Kinase, Janus Kinase 2, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.